MCM
IMDZ

Moore Capital Management’s Immune Design Corp. IMDZ Stock Holding History

Moore Capital Management’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-100,000
Closed -$390K – 349
2017
Q4 		$390K Buy
+100,000
New +$545K 0.01% 240

Other funds holding IMDZ

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Moore Capital Management's IMDZ Position: Q1 2018 in Review

Moore Capital Management sold out of Immune Design Corp. (IMDZ) in Q1 2018, closing a stake of 100,000 shares — an estimated $390K sold.

Moore Capital Management first reported a position in IMDZ in Q4 2017 and held it in 1 quarter. The position peaked at $390K in Q4 2017. 72 funds tracked by Wall St. Rank hold IMDZ as of Q1 2018.

  • Moore Capital Management reported no remaining Immune Design Corp. position as of Q1 2018 after selling out during the quarter.
  • Moore Capital Management sold 100,000 Immune Design Corp. shares in Q1 2018, an estimated $390K.
  • Moore Capital Management first reported a position in Immune Design Corp. in Q4 2017 and held it in 1 quarter.
  • Moore Capital Management's Immune Design Corp. position peaked at $390K in Q4 2017.
  • 72 funds tracked by Wall St. Rank held Immune Design Corp. as of Q1 2018.

Based on Moore Capital Management's 13F filing for Q1 2018, filed 15 May 2018.